Latest News

TERIS trial: final results

 

The TERIS trial of teriflunomide in individuals with radiologically isolated syndrome (RIS) has reported that treatment significantly prolonged the time to a first clinical event by 63% versus placebo (Lebrun-Frenay et al. JAMA Neurol, epublished August 21, 2023). Read More

TOPICS:

New ECTRIMS/EAN recommendations for vaccination in MS patients

 

The European Committee for Treatment and Research in MS (ECTRIMS) and the European Academy of Neurology (EAN) have published their first recommendations on vaccination in people with MS (Otero-Romero et al. Eur J Neurol 2023;30:2144-2176). The following is a summary of key recommendations for patients receiving higher-efficacy disease-modifying therapies (DMTs). Read More

MicroRNAs – their potential as MS biomarkers

 

MicroRNAs are short (21-25 nucleotides) non-coding RNA molecules that regulate gene expression by activating or repressing mRNA transcription. About 2000 have been identified thus far (Kozomara et al. Nucleic Acids Res 2019;47:155-162), and many have potential utility as biomarkers in the diagnosis, monitoring and treatment of multiple sclerosis. Read More